USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$54.67B
Market Cap
37.6
P/E Ratio
23.35
EPS
$934.62
52 Week High
$510.06
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$83M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $18M |
| Capital Expenditures | $68M |
| Change In Receivables | - |
| Change In Inventory | -$96M |
| Profit Loss | - |
| Cashflow From Investment | -$718M |
| Cashflow From Financing | $280M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$22M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $833M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
argenx NV, based in Breda, the Netherlands, is a leading clinical-stage biotechnology company focused on developing innovative antibody-based therapies for severe autoimmune diseases, hematological disorders, and cancer. Leveraging its proprietary technology platform, argenx is advancing a robust pipeline of therapeutic candidates through multiple clinical trial phases, with the objective of delivering transformative solutions to patients with significant unmet medical needs. As the company continues to capitalize on scientific breakthroughs and expand its portfolio, argenx represents a compelling investment opportunity for institutional investors seeking exposure to the dynamic biopharmaceutical sector.